Specimen Reception and NDDL over Public Holidays:
The Florey closes for Victorian and National Public Holidays. Please hold all diagnostic samples at -20oC during affected periods. Contact us for further information about Specimen Reception at the NDDL.
NATA/RCPA accreditation number 19256
Cerebrospinal Fluid Alzheimer Disease Screen
Abeta1-42, Tau, Phospho-Tau
The Cerebrospinal Fluid (CSF) Alzheimer Disease Screen is an ante-mortem diagnostic test that detects alterations in the levels of biomarker proteins, specifically amyloid Abeta42, total-tau and phospho-tau, which are believed to be directly related to the pathophysiology of Alzheimer's disease (AD). Based on international experience, these CSF biomarkers offer approximately 80-90% sensitivity and specificity for clinically overt AD and valuable prognostic information in persons with amnestic mild cognitive impairment (1). The recommendations detailed for CSF handling align with the consensus statement issued by the Alzheimer's Biomarker Standardisation Initiative (2,3).
- must be collected directly into the polypropylene tube – Please download the sample collection sheet here
- must be accompanied with the Specimen Data Sheet – Please download the CSF Alzheimer's disease Screen specimen data sheet here
Diagnostic Testing Fees
AD screen (three proteins) $190; any two proteins $150; any single protein $100 (this test is non Medicare rebatable).
The test is run fortnightly, except insufficient samples.
National Dementia Diagnostics Laboratory (NDDL)
The laboratory is headed by Professor Steven Collins, Professor Colin Masters and Dr Qiao-Xin Li.
Dr Qiao-Xin Li
National Dementia Diagnostics Laboratory
Florey Institute of Neuroscience and Mental Health
Kenneth Myer Building / Melbourne Brain Centre
30 Royal Parade (corner of Genetics Lane)
Enter via Gate 11, rear loading dock
Parkville Victoria 3010
Phone: (03) 9035 7243
Facsimile: (03) 9035 8768
1. Hulstaet et al. Neurology 1999; 52:1555; Hansson et al., Lancet Neurol, 2006;5(3):228-34; Buchhave et al. Arch Gen Psychiatry 2012; 69: 98-106. Li et al. J Alzheimers Dis, 2015; 48:175-187.
2. Vanderstichele et al. Alzheimer's and Dementia 2012; 8:65-73.
3. This laboratory is a member of the Alzheimer's Association QC program.
14-3-3 CSF Protein Test
The 14-3-3 protein is an ante-mortem, non-specific marker of central nervous system neuronal injury or death. Based on international experience in carefully selected patients, a positive result by Western blotting has approximately 90% sensitivity and specificity for sporadic Creutzfeldt Jakob disease. False positives are recognized in various disease processes; for example encephalitis, encephalopathies and recent cerebral infarcts. Unselected sampling is consequently less reliable if the 14-3-3 protein CSF test is used to screen for a possible diagnosis of CJD. The Australian National Creutzfeldt-Jakob disease Registry (ANCJDR) is the only diagnostic laboratory in Australia that provides 14-3-3 CSF protein testing.
For specific details regarding the specimen requirements and reception, please refer to the main ANCJDR website or contact the ANCJDR main office
Phone: (03) 8344 1949
Fax: (03) 9349 5105